Financebotresearch desk研究台

RKLB › analyze

RKLB · Analyze smallcap

WATCH Infrastructure

2026-08-30 · $64.39 · Mkt cap $41.17B · EV $36.4B (vendor) / ~$40B (corrected) · −57.4% off the $151.00 high

This is a /analyze-smallcap re-frame of the full /analyze report written three days ago (2026-08-27, WATCH 4.5). Nothing material moved in the intervening three days — price drifted from $67.53 to $64.39, which matters mechanically (below) — so this report leans on that report's verified numbers and re-applies the §6 risk-forward Startup framework rather than re-deriving the fundamentals from scratch. See that file for full line-item detail.

🚩 RED FLAGS — read this section first

  1. Neutron has slipped five times in five years and has still not test-fired as an integrated stack. Baseline target was 2024; current guidance is Q4 2026 with the CEO himself telling investors on the Q2 call that "the window is narrowing." Prediction markets price ~14% odds of a launch before 2027. Every part of this thesis — the Iridium synergy, the profitability path, the moat argument against SpaceX — routes through a rocket that has not flown.
  2. The company just agreed to buy Iridium for ~$8.0B on a $3.6B bridge, taking pro-forma net debt from −$2.4B to an estimated +$3–4B (≈7–9x combined EBITDA unless a large slug is equitised). The stated synergy — cheap, self-launched constellation replenishment — is entirely conditional on Neutron flying and flying often.
  3. The stock is now trading below the merger's exchange-ratio collar floor ($67.50). At $64.39, the ratio is fixed at its worst level for RKLB (0.4000 shares per IRDM share) — the collar stopped protecting the deal exactly where protection matters, and it gets worse the lower the price goes between now and the mid-2027 close.
  4. Share count is up ~10% in six months (543.6M → 598.2M common between 2025-12-31 and 2026-06-30, plus preferred), funded by a live $1.944B ATM whose lenders (Deutsche Bank, Wells Fargo) are the same two banks holding the Iridium bridge — the mechanism by which the bridge gets taken out with equity. A further 7.45M shares of collared forward sales settle April 2028, already sold but not yet in the share count.
  5. Zero open-market insider purchases exist in the record — ever, by anyone. The CEO's trust has sold roughly $555M across three tranches since September 2025; two directors have sold repeatedly. The August 24 "$5.5M insider selling" headline is a same-day, pro-rata, company-administered RSU tax sell-to-cover (Form 4 code S, confirmed against the cash-flow statement's "RSU sales to cover taxes" line) and is not a discretionary signal — but its absence of any offsetting purchase is.
  6. Operating loss has been flat at −$51M to −$60M for five straight quarters while revenue grew 62%. Every dollar of gross-margin leverage (53% incremental gross margin — a genuinely good number) is being absorbed by R&D, which is Neutron. Adjusted EBITDA loss is guided to widen in Q3.
  7. A customer delivery delay is disclosed with an unquantified liquidated-damages exposure; the same customer (MDA Corporation) was 11% of receivables at quarter-end.
  8. Sell-side targets sit 55–80% above spot (mean $112.94, zero Sells) — a gap this reviewer reads as the Street still marking to a 2026 Neutron flight that is no longer the base case, not as an underpriced stock.

🟢 Offsetting, real, and worth naming: a $2.36B backlog of which ~$1.83B is signed US defence work; SDA prime contractor status (a rare tier jump); 100% Electron mission success (93 flights); a coherent ~$470M M&A strategy that bought supply-chain bottlenecks (Mynaric optical terminals, Geost payloads, Motiv mechanisms) rather than revenue; and the $355M convertible note issue has essentially fully converted to equity, removing that overhang cleanly.

1. CLASSIFY — Startup

Rocket Lab is unambiguously the Early–Middle Startup archetype under §6.1: a company that IPO'd via SPAC in 2021, has never been GAAP-profitable, is rapidly expanding revenue (+62% YoY), and whose bull case depends on a still-unproven product (Neutron) rather than a turnaround from past scale. Apply the Startup lens in full: weight TAM, growth CAGR, runway, product-market fit and founder quality — not debt workout credibility.

Default prior applies: ~90% of Startups like this fail or stagnate below plan. The burden of proof is on the bull case, not the bear case. What has cleared that bar so far is narrow and specific — Space Systems and HASTE — not the company as a whole.

2. SURVIVAL METRICS

Cash runway — not the acute risk here, which is unusual for this framework

H1 2026
Operating cash flow −$134.4M (≈ −$67M/quarter)
Capex $53.1M
Free cash flow −$187.5M (≈ −$94M/quarter)
Cash + securities, 30 Jun 2026 $2.387B

Standalone runway on the operating business alone is roughly 25 quarters (~6 years) of FCF burn at the current rate — this is not a going-concern name, and that distinguishes it from most of the field swept in Themes/smallcap-defense-space-drones.md. The real survival question is not operating cash, it is the ~$4.7B cash requirement the Iridium deal adds on top of it (cash consideration + debt retirement), financed by a bridge that must be taken out with equity issuance into whatever price prevails between now and mid-2027. Reframe: this is a company that doesn't need to raise to survive, but is choosing to lever up and dilute to buy an income statement before its core product has flown.

Burn trajectory

Widening, by design: R&D +46% YoY ($55.1M → $80.5M) is Neutron spend, and adjusted EBITDA loss is guided to widen further in Q3 (−$8.8M → −$17M to −$23M). Not a breakeven path in sight until Neutron reaches meaningful cadence (see §4).

Dilution risk — the correct lead metric for this name, not cash runway

  • +54.6M common shares in six months (~10%), additional paid-in capital +$1.87B.
  • ATM history escalating: $750M (Mar'25, $396.6M drawn) → $1.0B (Mar'26, terminated) → $3.0B (May'26, $1,055.6M sold) → $1.944B remainder live now (Aug'26), rolled to the same banks underwriting the Iridium bridge.
  • 7,451,200 shares of collared forward sales settling April 2028 (~$474–642M expected proceeds) — sold forward, not yet in the count.
  • The Iridium exchange-ratio collar is now pinned at its floor (0.4000 at ≤$67.50; spot is $64.39) — deal dilution is fixed at its maximum, and every further point of downside before close adds nothing back in protection.

Verdict: dilution, not cash, is the risk that erodes an owner's per-share value here. Per-share value has been diluted roughly 10% every six months while the operating business still burns; a pro-forma count near 680–700M+ is coming once Iridium closes.

Debt & maturities

Total liabilities pre-deal are trivial (~$695M; total debt ~$15M, so the vendor-reported D/E of 3.83x is a data artifact, not real leverage — see pitfall flag below). Pro forma with Iridium, net debt swings to +$3–4B on a $3.6B 364-day bridge, ~7–9x combined EBITDA unless equitised. The debt risk is entirely forward-looking and entirely a management choice, not a legacy balance-sheet problem.

3. LIQUIDITY / VALUATION — no earnings, no dividend; Graham/DDM/DYT do not apply

Graham's radicand is negative (EPS −$0.27); there is no dividend. Per §3 of analysis_notes.md, pre-profit speculative names are valued on EV/revenue vs. peers, TAM-penetration scenarios, and reverse-DCF only.

⚠️ Vendor traps, unchanged from three days ago — confirm before trusting any screen: EV understates true enterprise value by ~$3-4B (ignores the 41M preferred shares and misreads net cash); epsForward/PE(fwd) of ~1,288x is priced off FY2027, while epsCurrentYear of −$0.045 confirms FY2026 is a loss ([[pitfall-vendor-forward-eps-is-the-wrong-fiscal-year]]); sharesOutstanding (598.5M) excludes ~41M preferred that market cap already counts; the D/E of 3.83 is meaningless against ~$15M of actual debt.

Multiple Value
EV ÷ TTM revenue ($769.1M) ~53x (corrected EV) / 47.3x (vendor EV)
EV ÷ FY2026E revenue (~$977M) ~42x
Pro forma with Iridium (EV ~$48.8B ÷ ~$1.85B combined revenue) ~26.5x
Pro forma EV ÷ combined EBITDA (~$460M) ~106x

Reverse-DCF — what today's $40B+ enterprise value actually requires: exit at 5x sales in 7 years needs $15.9B of revenue, a 53.7% CAGR from today's $769M; in 10 years, $21.2B, a 39.4% CAGR. For scale, $19–21B of revenue is larger than Lockheed Martin's entire space segment. The price is not asking Rocket Lab to be a good company — it is asking it to become one of the largest space companies on the planet inside a decade, from a base that is currently losing money on operations.

Sum-of-parts (Space Systems at 10–20x sales, Launch/HASTE at 10–15x sales, Neutron success-probability-weighted, plus net cash) lands at $20–39/share, i.e. materially below spot. Fair value range $25–45, central ~$34. Entry zone $28–36. Strong-conviction buy only below $24. At $64.39 the price is roughly 1.9x the central case — there is no entry today, and the 52-week low ($37.57) is itself above the top of the fair-value range's floor.

What has to go right to justify $64.39: Neutron flies successfully in 2027 (not the current base case), reaches a cadence of ~10-12 flights/year to hit breakeven (2029–2031 on the honest Falcon-9 development-speed comparison), the Iridium deal closes on schedule and delevers rather than compounding leverage, and Golden Dome converts from a demonstration selection into an actual signed contract. That is four unproven-to-partially-proven events stacked, priced as though most of them are already resolved.

4. SENTIMENT — the lead signal, per §6.3

Institutional/sell-side tone: Consensus Buy, 0 Sells, mean target $112.94 (+75% from spot) — but the single most informative data point is BTIG's August 20 downgrade to Hold, the only rating action issued after both the Q2 print and the CEO's "window is narrowing" comment. That is the tape catching up to the schedule risk, not the reverse.

Insider tone: no purchases, ever. Rated per §6.3's scale — attitude: neutral-to-cautious sell-side, founder diversifying steadily; financial pressure: low on operations, high and self-inflicted via the Iridium bridge; investor attitude: still optimistic (0 Sells) but visibly cracking (the BTIG downgrade); trajectory: revenue accelerating, losses steady, leverage about to step-change upward.

Golden flags: 100% Electron/HASTE mission success record; SDA prime status (Lockheed-tier, rare for a company this size); genuine bottleneck ownership via the Mynaric/Geost/Motiv acquisitions; convertible-note overhang resolved cleanly via conversion.

No golden flag on insider buying — the one category §6.3 calls a "strong golden flag" is entirely absent from this name's five-year public record.

5. MOAT & MARKET — adversarial stress test

As SpaceX: the structural threat is not close. Falcon 9 lists ~$67–70M against an estimated ~$15M internal cost; Neutron's targeted $50–55M sits ~3.5x above that marginal cost. SpaceX can cut Falcon 9 pricing and stay profitable, deleting Neutron's commercial argument the moment it wins anything meaningful. Rocket Lab's defence is non-price: customers who won't fly on a Starlink competitor (a set that, after Iridium closes, includes Rocket Lab itself) and government mandates for a second source.

As Relativity (Terran R): targeting the same 2H-2026 launch window, backed by Eric-Schmidt-scale capital — whoever flies first claims the "credible Falcon-9 alternative" positioning.

As Stoke Space (Nova): fully reusable, more ambitious architecturally — a lower-probability, higher-consequence 2028+ threat.

Where the moat holds: HASTE has no rideshare substitute and a 100% mission-success record since 2023 ($456M contracted across MACH-TB and USSF Kodiak); the SDA prime position and the independent-vertically-integrated-smallsat-manufacturer position (the only other credible peer, York Space, is private) are real and durable. This is a policy-conferred moat — the US government wants and will pay for a credible non-SpaceX vendor — not a cost-structure moat. Neutron's target margin "survives only in a world where SpaceX chooses not to compete on price." That world may persist (SpaceX is capacity-constrained by its own Starlink manifest), but the economics are granted, not defended.

Niche defensibility, per §6.4: strong in Space Systems/HASTE (a small, well-funded incumbent with real switching costs via bus/payload/laser-comms vertical integration); weak-to-unproven in medium-lift launch, where the incumbent (SpaceX) is both larger and structurally cheaper.

6. CATALYSTS — dated, rated likelihood × impact × direction

Catalyst Date Likelihood Impact Direction
LC-3 integrated static fire (fully-fuelled stack) Undated, "window narrowing" per Aug 10 report Medium Very high — the single most informative event on the thesis Could cut either way
Neutron first launch Guided Q4 2026, press reports possible slip to 2027 Low-medium Very high Bull if clean; existential-doubt if it fails or slips again
Q3 FY26 print ~2026-11-10 Certain (date) Medium Watch non-GAAP gross margin vs. 35–37% guide and share count vs. 641M guide, not the revenue headline
Iridium shareholder vote / deal close ~mid-2027 High (deal likely completes) High — sets pro-forma leverage and share count Levers the balance sheet either into a real second income statement or into a debt problem
Golden Dome conversion to contract Undated, currently a demonstration selection only Low-medium High if it converts Currently $0 — not yet revenue

Separate real catalysts from wishful thinking, per §6.5: the LC-3 static fire and the Neutron launch are the only two events that actually resolve uncertainty. The Q3 print resolves nothing new (guidance is already given); Golden Dome is a selection, not a contract, and should not be modeled as revenue until it converts.

7. RISK-FORWARD VERDICT

Risk rating: Speculative — Startup archetype, story-and-backlog-driven, thesis intact but priced for near-flawless execution. Not Turnaround-style balance-sheet risk; the balance sheet risk here is self-inflicted (Iridium) rather than inherited.

[4.0] WATCH. This is a genuinely improving business — 62% revenue growth, 53% incremental gross margin, a $2.36B backlog that is 75%+ signed defence work, and an SDA prime contractor tier jump — wearing a valuation that requires Neutron to fly on a timeline it has already missed five times, the Iridium deal to close and delever on schedule, and a decade of ~40-54% compound revenue growth to a scale larger than Lockheed's entire space segment. The price is pricing near-flawless execution on all three; the base case, on the evidence, is that Neutron slips into 2027 and cadence-10 profitability lands 2029–2031.

Not SPECULATIVE-BUY: no margin of safety exists at $64.39 against a $25-45 fair-value range — the entry zone ($28-36) requires roughly a 45-55% further drawdown, which the stock has visited before (52-week low $37.57) but is not at now.

Not AVOID: the thesis is not broken. Unlike names in the field's graveyard ([[pitfall-not-investable-universe]]: ASTR, Virgin Orbit, Volocopter), Rocket Lab has real contracted revenue, a real moat in Space Systems/HASTE, ample standalone cash runway, and a cleanly-resolved convertible overhang. This is "wait for the price or wait for the static fire," not "structurally uninvestable."

A portfolio-specific passage was removed from the public build.

8. WHAT WOULD CHANGE THE VERDICT

Toward AVOID / drop the thesis: - Neutron formally slips to 2028, or a second hardware failure occurs in qualification - The integrated static fire does not happen by 2026-12-31 - Iridium deal terminates, or the bridge is repriced/resyndicated on worse terms - Non-GAAP gross margin below 33% for two consecutive quarters - Share count above 720M before the deal closes (ATM drawn beyond deal requirement) - The MDA liquidated-damages exposure crystallises as a material charge

Toward SPECULATIVE-BUY (raise conviction, confirm the entry zone): - A successful integrated static fire on LC-3 — worth a full re-underwrite on its own - Neutron flying successfully — changes the entire valuation frame - Golden Dome converting from demonstration to signed contract - Iridium closing with more than half the cash leg funded by debt rather than fresh equity - Any open-market insider purchase — there has never been one in the record - Price actually reaching the $28-36 entry zone without a thesis-breaking reason for the drop

Recheck: Q3 FY26 print, ~2026-11-10, but the LC-3 static fire — whenever it happens — is the real trigger and should prompt an immediate re-visit regardless of the calendar.

APPENDIX — carried forward from the 2026-08-27 baseline, still unverified

  • Neutron's $50-55M contracted price per launch (secondary-source)
  • Falcon 9's ~$15M internal cost (industry estimate, not company-disclosed)
  • Press attribution of Iridium's rival bidders to AST SpaceMobile/Viasat — explicitly unconfirmed in the merger filing
  • Any material warrant overhang — absent from the 10-Q but not affirmatively confirmed zero
  • The pro-forma share count, leverage and EV figures in this report are derived arithmetic from the S-4/A terms, not company-disclosed pro formas